Literature DB >> 2297494

The effect of adrenalectomy and dexamethasone on interleukin-1 alpha induced responses in RIF-1 tumours.

P G Braunschweiger1, C S Johnson, N Kumar, V Ord, P Furmanski.   

Abstract

In the present studies the effect of bilateral adrenalectomy on the pathophysiologic responses to recombinant human interleukin-1 alpha (rHIL-1 alpha) was determined in RIF-1 tumour models. Acute vascular injury and haemorrhagic responses were quantitated by the intra-tumour accumulation of 59Fe radiolabelled erythrocytes. In vivo clonogenic tumour cell kill was determined by an excision assay. A single, intraperitoneal rHIL-1 alpha treatment (6.25 x 10(7) D10 units kg-1, 25 micrograms kg-1) resulted in acute tumour haemorrhage and approximately 55% clonogenic tumour cell kill (24 h). Bilateral adrenalectomy, 24 h before rHIL-1 alpha, significantly increased haemorrhagic responses, but haemodynamic toxicity was severe. This toxicity could be ameliorated by giving dexamethasone (5 mg kg-1) before or up to 3 h after rHIL-1 alpha. The effect of dexamethasone on rHIL-1 alpha induced tumour responses in adrenalectomised mice was sequence dependent. Given before rHIL-1 alpha, dexamethasone inhibited tumour haemorrhage. When dexamethasone was given up to 3 h after rHIL-1 alpha, tumour haemorrhage was directly related to sequence interval. Although adrenalectomy and dexamethasone alone had little effect on RIF-1 tumours, adrenalectomy increased rHIL-1 alpha mediated clonogenic tumour cell kill. The surviving fraction 24 h after rHIL-1 alpha (6.25 x 10(7) D10 units kg-1, 25 micrograms kg-1) and dexamethasone (5 mg kg-1, 2 h after rHIL-1 alpha) was 1.3 +/- 0.4%. The surviving fraction after this combination in intact mice (36.7 +/- 1.4%) was approximately 30-fold higher than that seen in adrenalectomised mice. The results indicate that adrenal responses secondary to rHIL-1 alpha treatment exert a negative feedback on rHIL-1 alpha mediated responses in solid tumours.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297494      PMCID: PMC1971311          DOI: 10.1038/bjc.1990.4

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  The effect of anti-inflammatory agents and inflammation on granulocyte adherence. Evidence for regulation by plasma factors.

Authors:  R R MacGregor
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

2.  Interleukin-1 and glucocorticoid hormones integrate an immunoregulatory feedback circuit.

Authors:  A Del Rey; H Besedovsky; E Sorkin; C A Dinarello
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

3.  Synergistic anti-proliferative activity of interleukin 1 and tumor necrosis factor.

Authors:  V Ruggiero; C Baglioni
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

Review 4.  Vascular actions of leukotrienes.

Authors:  L G Letts; M Cirino
Journal:  Prog Clin Biol Res       Date:  1985

5.  Toxic effect of tumor necrosis factor on tumor vasculature in mice.

Authors:  N Watanabe; Y Niitsu; H Umeno; H Kuriyama; H Neda; N Yamauchi; M Maeda; I Urushizaki
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

6.  Effect of dexamethasone on vascular function in RIF-1 tumors.

Authors:  P G Braunschweiger; L M Schiffer
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

7.  Augmented antitumor effect of recombinant human interleukin-1 alpha by indomethacin.

Authors:  K Nakata; S Kashimoto; H Yoshida; T Oku; S Nakamura
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

8.  Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation.

Authors:  B Samuelsson
Journal:  Science       Date:  1983-05-06       Impact factor: 47.728

9.  The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.

Authors:  E A Havell; W Fiers; R J North
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor.

Authors:  R L Nachman; K A Hajjar; R L Silverstein; C A Dinarello
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  1 in total

1.  Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice.

Authors:  C S Johnson; M J Chang; W D Yu; R A Modzelewski; J R Grandis; D R Vlock; P Furmanski
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.